(1S,3Ar,6As)-Octahydrocyclopenta[C]Pyrrole-1-Carboxylic Acid Ethyl Ester

Direct application of (1S,3aR,6aS)-octahydrocyclopenta[c]pyrrole-1-carboxylic acid ethyl ester as a protected residue in Fmoc-based solid-phase peptide synthesis imposes stringent demands on resin substitution stoichiometry to prevent interchain aggregation and diketopiperazine formation. When the free carboxylic acid, liberated by treatment with 1.05 equiv of lithium hydroxide in a chilled mixture of THF/H₂O (4:1, v/v) at 0–2 °C for 90 min, is pre-activated with 1.0 equiv of 1-hydroxybenzotriazole (HOBt) and 1.0 equiv of N,N’-diisopropylcarbodiimide (DIC) in anhydrous DMF, and subsequently coupled to Rink amide MBHA resin (loading 0.55 mmol/g), the typical acylation efficiency exceeds 99.5% as determined by Kaiser test after 4 h. Residual unreacted hydroxyl sites are end-capped using Ac₂O/pyridine (1:2, v/v) for 20 min. The Fmoc group is removed with 20% piperidine in DMF containing 0.1 M HOBt to minimize aspartimide formation, and the resulting free secondary amine is then elongated using 4 equiv of incoming Fmoc-amino acid activated by HBTU/HOBt/DIEA in a 0.4 M solution. Double couplings of 45 min each are mandated for sterically demanding residues placed immediately adjacent to the bicyclic core. Final cleavage from the resin is effected with reagent K (TFA/thioanisole/phenol/water/EDT; 82.5:5:5:5:2.5) over 3 h, yielding a crude peptide with a C-terminal amide. The target oligomer containing the octahydrocyclopenta[c]pyrrole scaffold is typically employed as a β-turn mimetic in the development of peptidic inhibitors of protein-protein interactions, where the constrained dihedral angle distribution conferred by the cis-fused ring system improves target affinity by a factor of 10- to 100-fold relative to linear analogues. Regulatory documentation supplied to aseptic fill-finish contractors includes a TSE/BSE statement, confirmation of heavy metal limits below 10 ppm per Ph.Eur. 5.20, and a detailed mass balance for all organic volatile impurities per USP <467> Option 2.

Synthetic elaboration into chiral N,N’-dioxides or phosphoramidite ligands for catalytic asymmetric transformations commences with LiAlH₄ reduction of the ester to the corresponding primary alcohol. The reduction is run in anhydrous THF at 0–5 °C under argon, using 1.8 equivalents of lithium aluminum hydride powder added portionwise over 1 h; the mixture is then heated to 40 °C for 2 h to ensure complete conversion. After Fieser workup and filtration through a Celite pad, the (S)-hydroxymethyl derivative is obtained as a pale-yellow oil in 85–88% yield. Swern oxidation (DMSO, oxalyl chloride, Et₃N, −78 °C to 0 °C) furnishes the aldehyde, which is immediately condensed with (S)-tert-leucinol in the presence of 4 Å molecular sieves in dichloromethane, generating a Schiff base that is reduced in situ with sodium triacetoxyborohydride (1.5 equiv) at pH 5 to afford the secondary amine ligand precursor in 72% overall yield. The crude amino alcohol is treated with 2.2 equivalents of zinc chloride in acetonitrile and 3.0 equivalents of cyanogen bromide to form the oxazoline ring; after 16 h at 60 °C, the reaction yields a bidentate bis(oxazoline) ligand that, when complexed with 10 mol% copper(II) triflate, catalyzes the enantioselective Diels–Alder addition of cyclopentadiene to 3-acryloyl-2-oxazolidinone. At −20 °C in CH₂Cl₂, the exo product is isolated with an endo/exo ratio of 96:4 and an enantiomeric excess of 98.5% (determined by chiral SFC, Chiralpak AD-H, 30% MeOH co-solvent, 2.5 mL/min, 220 nm). Scale-up above 500 g is hampered by the thermal liability of the cyanogen bromide adduct; containment within a Hastelloy C-22 reactor with a continuous N₂ sweep and immediate quenching of off-gas through a 20% NaOH scrubber is prescribed to manage toxic by-products. The final ligand is rigorously dried in vacuo at 40 °C / 0.1 mbar for 48 h and supplied under nitrogen in septum-sealed glass bottles to prevent moisture-induced hydrolysis of the oxazoline rings.

Why Is Precise Temperature Control Critical During Lithiation-Mediated α-Alkylation?

Construction of quaternary stereocenters via deprotonation of the N-Boc protected ethyl ester with lithium diisopropylamide (LDA) is exceptionally sensitive to the internal reaction temperature profile due to competing enolate racemization through a charge-transfer pathway. In a typical procedure, the N-Boc derivative is dissolved in anhydrous THF (0.15 M) and cooled to −78 °C (dry ice/acetone) in a jacketed reactor equipped with a Pt100 probe. Freshly prepared LDA (1.3 equiv, 0.8 M in THF/hexanes) is added dropwise at a rate of 0.4 mL/min per mole of substrate to ensure the internal temperature never exceeds −65 °C. After stirring for 45 min, the resulting lithium enolate is treated with a pre-cooled solution of the alkyl iodide (2.0 equiv) in THF, maintaining the temperature below −50 °C. Quenching is performed by pouring the mixture into saturated NH₄Cl at 0 °C. Under these conditions, α-methylation of the bicyclic ester consistently gives the (1S,3aR,6aS)-2-methyl derivative in 91% yield with a diastereomeric ratio (d.r.) of 95:5. However, if the enolate is allowed to warm to −30 °C for even 10 min before electrophile addition, the d.r. deteriorates to 75:25 and overall conversion drops by 15% due to decomposition. Reaction calorimetry data recorded on a Mettler-Toledo RC1 indicate an adiabatic temperature rise of +38 °C for the neutralization step, mandating a cooling capacity of at least −50 W/kg at −20 °C for pilot-scale batches. The quaternized intermediates serve as advanced building blocks for macrocyclic Factor VIIa inhibitors and are produced in quantities up to 15 kg per campaign following ICH Q7 guidelines for GMP manufacturing. Each batch is certified for enantiomeric purity by chiral HPLC (Chiralpak IC, 5 µm, 4.6 × 250 mm; mobile phase n-heptane/EtOH/TFA 95:5:0.1; 1.0 mL/min, 205 nm); the limit for the undesired (1R,3aS,6aR)-epimer is set at ≤0.5%. Any out-of-specification lot is reprocessed via fractional crystallization of its D-tartrate salt.

Weinreb Amide Formation Preserves Configuration in HCV Inhibitor Assembly

The ethyl ester is converted into a Weinreb amide as a strategic intermediate for ketone installation without epimerization at the sensitive α-carbon. To a suspension of N,O-dimethylhydroxylamine hydrochloride (1.5 equiv) in anhydrous THF at −15 °C is added isopropylmagnesium chloride (1.4 equiv, 2.0 M in THF), and the resulting dimethylhydroxylamide solution is aged for 30 min. A solution of the bicyclic ester in THF is then metered in over 60 min while keeping the jacket temperature at −10 °C. After 2 h, the reaction is quenched with 10% citric acid and extracted with MTBE; the Weinreb amide is isolated in 93–96% yield as a crystalline solid after trituration with cold heptane. Subsequent Grignard addition with 4-bromopyrazole Grignard (1.3 equiv, freshly prepared in THF) at 0 °C delivers the ketone, which is telescoped into a reductive amination with a P1-P3 tripeptide surrogate. The resulting acyclic precursor undergoes ring-closing metathesis using 5 mol% Hoveyda-Grubbs II catalyst in toluene at 0.005 M to form the macrocyclic ring. Prolonged high-dilution conditions (18 h, 70 °C) are critical to suppress oligomeric by-products; the macrocyclization yield plateaus at 78%. Downstream, the ethyl ester is hydrolyzed with LiOH and the resulting carboxylic acid is coupled to cyclopropanesulfonamide via EDC/HOAt to deliver the acylsulfonamide pharmacophore. The final compound is a non-covalent, reversible NS3/4A protease inhibitor with a Ki in the low nanomolar range. Residual palladium and ruthenium content in the API must be controlled below 10 ppm and 5 ppm, respectively, as verified by ICP-MS per Ph.Eur. 2.4.20, and the process is validated over three consecutive PPQ batches of 5 kg scale. Any batch exceeding the heavy metal threshold is subjected to a second charcoal treatment with 1.5% w/w activated carbon at 60 °C.

When Diastereomeric Salt Resolution with Dibenzoyl-L-tartaric Acid Outperforms Chromatography

For manufacturing campaigns where chromatographic purification is cost-prohibitive, the racemic ethyl ester is subjected to classical resolution using dibenzoyl-L-tartaric acid (L-DBTA) as the resolving agent. The racemate is dissolved in acetone/water (9:1 v/v, 10 mL/g substrate) and heated to 50 °C. Solid L-DBTA (0.52 equiv) is added in one portion, the solution is stirred for 15 min to obtain a clear solution, and the mixture is then allowed to cool to 32 °C over 2 h, at which point spontaneous nucleation occurs. The suspension is then cooled linearly to 5 °C at a rate of −2 °C/h using a programmable circulator and aged at 5 °C for an additional 12 h. The precipitated diastereomeric salt is collected by filtration, washed with cold acetone, and recrystallized a second time from the same solvent system to afford the (1S,3aR,6aS)-ester·L-DBTA adduct with a diastereomeric excess ≥99.7% (measured as the N-benzoyl derivative on a C18 column). The free base is liberated by partitioning between ethyl acetate and 1 M NaOH at 0 °C, dried over Na₂SO₄, and isolated in an overall recovery of 42% with respect to the racemate. This material meets the specifications of a chiral HPLC purity of >99.0% area and specific rotation [α]_D²⁰ = −8.2 ± 0.5° (c 1.0, CHCl₃). The recycled mother liquors containing the enriched (R)-antipode are racemized by heating with 20 mol% DBU in ethanol at 78 °C for 8 h, allowing an overall mass yield above 85%. This approach complies with ICH Q11 guidance on the use of classical resolution as a suitable manufacturing route for chiral starting materials and eliminates the need for expensive simulated moving bed (SMB) equipment at throughputs up to 200 kg/year.

Evaluation of novel amylose- and cellulose-derived chiral stationary phases under subcritical fluid chromatography (SFC) conditions frequently employs the enantiomeric pair of octahydrocyclopenta[c]pyrrole-1-carboxylic acid ethyl ester as a benchmark probe to quantify column selectivity and peak symmetry. The N-acetyl derivative is prepared by reacting the neutralized free amine with acetic anhydride (1.2 equiv) in dichloromethane in the presence of pyridine at 25 °C for 1 h; the acetylated enantiomers are then separated on a variety of columns at 40 °C back-pressure 150 bar, using a CO₂/MeOH (90:10) mobile phase at 3.0 mL/min total flow. For the (1S,3aR,6aS) enantiomer, retention times range from 1.8 min on Chiralpak IH to 4.2 min on Chiralcel OZ-H. The selectivity factor α averages 1.15 on polysaccharide-based phases and drops to 1.02 on brush-type Pirkle columns, thereby providing a practical metric for screening column fitness for preparative-scale supercritical fluid separations of bicyclic amines. Method robustness is evaluated by deliberate introduction of 0.5% water into the modifier and monitoring the resolution factor Rs; a decrease below 2.0 signals the need for modifier husbandry. The analytical data package distributed to third-party manufacturers includes a tabulated comparison of LOD values (Table 1).

Residual Genotoxic Impurity Control in the Context of ICH M7

Synthesis of the ethyl ester via Fischer esterification or transesterification pathways inevitably introduces trace levels of ethyl methanesulfonate (EMS) and ethyl p-toluenesulfonate (EPTS), both classified as potential genotoxic impurities requiring dedicated purge factor studies. The intermediate is subjected to a polishing step consisting of column percolation through activated carbon (Norit CN1, 5% w/w) in n-heptane solution at 60 °C for 2 h, followed by hot filtration and distillation at reduced pressure (0.1 mbar, 85 °C oil bath). This treatment reduces sulfonate esters to ≤0.5 ppm as quantified by GC-MS operated in selected ion monitoring (SIM) mode (m/z 79, 109). For custom syntheses destined for Phase I clinical trials, a staged TTC approach with an allowed daily intake of 1.5 µg/day per individual impurity is applied, in accordance with ICH M7 Option 1. Where the maximum daily dose of the final API is projected to be 500 mg, the concentration limit in the intermediate must not exceed 3 ppm. A mass balance and fate/purge rationale is included in the drug master file, demonstrating that the subsequent peptide coupling and aqueous workup steps afford a mean purge factor of 6.2 × 10⁴, thus eliminating the need for routine batch release testing of the downstream API for these genotoxins. Table 2 summarizes the harmonized residual solvent specifications adopted from ICH Q3C for this advanced intermediate.

Taking Configurational Lability into Account in Peptide Fragment Condensations

The α-proton adjacent to the ester carbonyl possesses a pKa of approximately 22 (calculated), rendering the stereocenter susceptible to deprotonation by tertiary amine bases commonly used in activation cocktails. Under standard coupling conditions with HATU/DIEA (3 equiv) in DMF at 25 °C, slow epimerization is observed, yielding 10% of the (R)-epimer after 4 h. In contrast, when PyBOP (1.05 equiv) and N-methylmorpholine (1.2 equiv) are employed at 0 °C in a 1:1 CH₂Cl₂/DMF mixture, epimerization is suppressed to ≤0.3%, as confirmed by derivatization with L-phenylalanine methyl ester and HPLC analysis on a SUMICHIRAL OA-6100 column. The constrained bicyclic system exacerbates the problem because the resultant enolate is stabilized by the planar configuration of the pyrrolidine ring, allowing racemization on a timescale comparable to that of the desired acylation. Consequently, industrial-scale peptide fragment condensations involving this intermediate are conducted in stainless steel reactors with a jacket temperature control accuracy of ±1 °C, and the sequence of reagent addition is strictly programmed: the carboxylic acid is pre-mixed with PyBOP and NMM for 2 min at −5 °C before the amine nucleophile is introduced as a single portion. The coupled product is then directly purified by seeded cooling crystallization from isopropyl acetate/heptane to eliminate any trace of the diastereomeric amide. Finished conjugates find application as orally bioavailable thrombin inhibitors and are released against a specification of diastereomeric excess ≥99.5%. For long-term storage, the intermediate is supplied as its tosylate salt to prevent intramolecular cyclization and moisture ingress.